Advancing RNA Newsletter - 11.20.24 Tips For Addressing Vaccine Demand – Strategies For C&G And mRNA https://lnkd.in/etcGwdJu Subscribe Here: https://lnkd.in/eXFaf69d
Advancing RNA
互联网出版
Erie，Pennsylvania 2,613 位关注者
A trusted information source for professionals in the rapidly evolving field of RNA-based therapeutics.
关于我们
Advancing RNA is a Life Science Connect community focused on the rapidly evolving field of RNA-based therapeutics. It aims to provide valuable insights, discussions, and resources for professionals developing RNA-based drugs. Primary members of the community consist of individuals from biopharma organizations engaged in pre-BLA development, often in the pre-IND discovery stage. The community addresses various challenges in RNA therapy development, including analytical, quality, manufacturing, and regulatory issues. Additionally, Advancing RNA is positioned within the broader Life Science Connect network, allowing members to access additional resources as needed for their RNA therapy development journey.
- 网站
-
https://www.advancingrna.com/
Advancing RNA的外部链接
- 所属行业
- 互联网出版
- 规模
- 51-200 人
- 总部
- Erie，Pennsylvania
- 领域
- life sciences、rna-based therapeutics、biopharma和mRNA
动态
-
RNA Therapeutics: New Market Research https://lnkd.in/eFgnGPqE - By Pooja Sharma, Global Market Insights Inc. In addition to vaccines, RNA-based therapies are gaining traction for their promise in targeting cancers, genetic disorders, and rare diseases.?
-
-
RNA Therapeutics: Navigating The "Holy Trinity" Of Structure, Process, & Biology https://lnkd.in/eyUtk6aU "Our conversation ultimately gravitated back to some of the biggest questions we currently have and need to answer about our product’s structure and function — and how to adequately demonstrate this critical knowledge to regulators." - Anna Rose Welch in a discussion with Bernard Sagaert, CEO of etherna.
-
-
Though conversations about "scale" tend to home in on scale-up, this clip from my colleague Erin Harris' recent live event gives us a much-needed alternative perspective: Scaling down--especially for personalized approaches--and/or working with small scales expose us to some rarely discussed supply chain management, COGS, and testing challenges. Some great points in this Advancing RNA clip from Christian Moreno and Joseph Barberio. Check it out!
-
Achieving Next-Generation mRNA-LNP Therapeutics Delivery https://lnkd.in/e_H8yJEJ Three LNP experts (Dr. Kate Zhang, Professor Ben Muir, and Dr. Sumit Luthra) parse out the current opportunities and unknowns facing the development of next-generation LNPs.
-
-
Were We (Are We) Correct About Oligonucleotides? https://lnkd.in/eUKAfnwG - By?Louis Garguilo, Chief Editor, Outsourced Pharma While the?predicted growth is remarkable, that we are already nearing $9 billion in oligo synthesis work worldwide this year?is quite a confirmation of how far?we've come.
-
-
If you woke up craving a great analysis of the current oligonucleotide market, this is the article for you. This week, Outsourced Pharma's Louis Garguilo unseats Tyler Menichiello for the (very coveted) title of ARW's "favorite colleague" (sorry Tyler and Matthew Pillar and Erin Harris and Dan Schell...). Here, in his latest article, Garguilo answers the very important question he poses in the article's title, with some help from a recent MarketsAndMarkets report on the oligo market. A must-read for those of us looking to learn more about mRNA's "older sisters" and what they've been up to in the past few years--as well as where they may be headed. Check it out!
Were We (Are We) Correct About Oligonucleotides?
advancingrna.com
-
There are a number of reasons why I struggle with the term "standardization" in the RNA space, so I was glad to hear Nutcracker Therapeutics' Christian Moreno and Strand Therapeutics' Joseph Barberio tackle this topic during my colleague Erin Harris recent Live event. Check it out here!
Tackling The Standardization Issue For mRNA Therapeutics
advancingrna.com
-
Achieving Next-Generation mRNA-LNP Therapeutics Delivery https://lnkd.in/ebeEkez9 It’s impossible to attend an event on the future of RNA therapeutics without hearing about the challenges we’re facing with targeted RNA-LNP delivery. In this final Advancing RNA Live discussion of 2024, we sat down with three LNP experts to parse out the current opportunities and unknowns facing the development of next-generation LNPs. Hear their takes on the latest scientific advancements/discoveries in LNP R&D to advance RNA-LNP delivery beyond liver, as well as the unique manufacturing and quality considerations such discoveries are currently posing to LNP developers striving to manufacture high-quality RNA-LNP therapeutics today.
-
-
RNAi excitement continues to grow with companies like ARGONAUTE RNA LIMITED and Kate Therapeutics securing funding to advance RNAi candidates and delivery platforms, along with microRNA work being awarded with a Nobel Prize in Medicine, there’s no better time to announce the 6th RNAi-Based Therapeutics Summit! Find out who you could join including Alnylam Pharmaceuticals, Benitec Biopharma Inc., and Eli Lilly and Company when you download the official brochure:?https://ter.li/j5sr78 USE CODE 56642ADR10 for a 10% discount!
-